A Prospective Trial of COXEN Chemotherapy Prediction

NCT01228942WithdrawnNAINTERVENTIONAL

Summary

The purpose of this study is to determine if the COXEN algorithm, using the diagnostic device Affymetrix GeneChip, is able to predict which chemotherapies will be best for treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.

Key Facts

Lead Sponsor

University of Virginia

Enrollment

0

Start Date

2010-10-01

Completion Date

2012-10-01

Study Type

INTERVENTIONAL

Official Title

A Prospective Trial of COXEN Chemotherapy Prediction in Persistent and Recurrent Ovarian, Fallopian Tube, and Peritoneal Carcinomas

Interventions

COXEN analysis for chemotherapy prediction

Conditions

Ovarian NeoplasmsFallopian Tube Neoplasms

Eligibility

Age Range

18 Years – 95 Years

Sex

FEMALE

Inclusion Criteria:

* age greater than 18
* diagnosis of recurrent, persistent, refractory ovarian, fallopian or primary peritoneal cancer
* tumor tissue, ascites or pleural fluid available for biopsy
* life expectancy greater than 6 months

Exclusion Criteria:

* patients with borderline or low malignant histologies
* patients with a history of other malignancies within last 5 years

Outcome Measures

Primary Outcomes

overall response rate

patient will have CT scans and CA 125 drawn to track response to chemotherapy

Time frame: 12 months

Secondary Outcomes

overall survival

patient will be tracked for life

Time frame: subject lifetime

Linked Diseases

Ovarian Neoplasms

Ovarian Neoplasms — a type of gynecological cancer.

A Prospective Trial of COXEN Chemotherapy Prediction